Skip to main content

AbbVie Inc. guidance

  • ABBV · NYSE
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$294.55−0.16%Close 16 Nov 2026 · Market value $517.6B

In its results release of 30 Oct 2026 (Q3 FY2026), AbbVie Inc. gave 1 forecast in figures, among them EPS (adjusted) of $13.95 to $13.99 for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 30 Oct 2026

MeasurePeriodGuidanceAs stated
EPS · Adjusted · RaisedFY2026$13.95 to $13.99Raises 2026 Adjusted Diluted EPS Guidance Range from $13.76 - $13.96 to $13.95 - $13.99, which Includes an Unfavorable Impact of $0.69 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2026

Source: the company's earnings release.

Guidance against results last two years

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
EPS · AdjustedFY2026$13.95 to $13.99Lowered twice—To come

ABBV in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.